Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. Sandoval, D., Poveda, R., Draibe, J., Pérez-Oller, L., Díaz, M., Ballarín, J., Saurina, A., Marco, H., Bonet, J., Barros, X., Fulladosa, X., Torras, J., & Cruzado, J. M. Clinical Kidney Journal, 10(5):632–638, 2017. doi abstract bibtex BACKGROUND: This study assessed the efficacy of therapy with mycophenolate (MF) and reduced doses of steroids in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome (SD/FR-INS). METHODS: Twenty-nine nephrotic patients (including 16 males and 13 females; mean age: 40 years, range: 18-74) were treated. Starting doses of MF were 2000 mg/day for mofetil MF (1500 mg/day in one patient) or 1440 mg/day for sodium MF. The initial prednisone (PDN) dose was 10 mg/day in 14 patients, 5 mg/day in two patients and no steroids in one patient. In the remaining 12 patients, moderate initial doses of PDN were administered (mean: 23.7 mg/day, range: 15-40), tapering to 10 mg/day after 1 month. RESULTS: Nephrotic syndrome remission was achieved in 27/29 cases (93.1%) (25 complete, 2 partial). Two patients showed resistance to the prescribed schedule. The first cycle of MF therapy was concluded in 20 patients after a mean (range) of 16.9 months (12-49). Maintenance of remission was observed in 11 of these 20 cases (55%) after a mean follow-up of 32.8 months (12-108). In nine patients with nephrotic syndrome relapse after tapering of MF (MF dependency), the same MF-PDN schedule was restarted, leading again to remission in all nine. The remaining seven MF-sensitive patients are still receiving their first therapeutic cycle. To date, the mean time under therapy in the 27 MF-sensitive patients is 38 months (4-216). Regarding complications, only minor digestive disorders and a slight decrease in blood haemoglobin levels were observed in a few patients. CONCLUSIONS: MF plus reduced doses of PDN is an effective and well-tolerated therapy for adult SD/FR-INS. Though MF dependence is observed, its low toxicity could allow long periods of therapy if it is required to maintain nephrotic syndrome remission.
@article{sandoval_efficacy_2017,
title = {Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome},
volume = {10},
issn = {2048-8505},
doi = {10.1093/ckj/sfx035},
abstract = {BACKGROUND: This study assessed the efficacy of therapy with mycophenolate (MF) and reduced doses of steroids in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome (SD/FR-INS).
METHODS: Twenty-nine nephrotic patients (including 16 males and 13 females; mean age: 40 years, range: 18-74) were treated. Starting doses of MF were 2000 mg/day for mofetil MF (1500 mg/day in one patient) or 1440 mg/day for sodium MF. The initial prednisone (PDN) dose was 10 mg/day in 14 patients, 5 mg/day in two patients and no steroids in one patient. In the remaining 12 patients, moderate initial doses of PDN were administered (mean: 23.7 mg/day, range: 15-40), tapering to 10 mg/day after 1 month.
RESULTS: Nephrotic syndrome remission was achieved in 27/29 cases (93.1\%) (25 complete, 2 partial). Two patients showed resistance to the prescribed schedule. The first cycle of MF therapy was concluded in 20 patients after a mean (range) of 16.9 months (12-49). Maintenance of remission was observed in 11 of these 20 cases (55\%) after a mean follow-up of 32.8 months (12-108). In nine patients with nephrotic syndrome relapse after tapering of MF (MF dependency), the same MF-PDN schedule was restarted, leading again to remission in all nine. The remaining seven MF-sensitive patients are still receiving their first therapeutic cycle. To date, the mean time under therapy in the 27 MF-sensitive patients is 38 months (4-216). Regarding complications, only minor digestive disorders and a slight decrease in blood haemoglobin levels were observed in a few patients.
CONCLUSIONS: MF plus reduced doses of PDN is an effective and well-tolerated therapy for adult SD/FR-INS. Though MF dependence is observed, its low toxicity could allow long periods of therapy if it is required to maintain nephrotic syndrome remission.},
language = {eng},
number = {5},
journal = {Clinical Kidney Journal},
author = {Sandoval, Diego and Poveda, Rafael and Draibe, Juliana and Pérez-Oller, Laureà and Díaz, Montserrat and Ballarín, José and Saurina, Anna and Marco, Helena and Bonet, Josep and Barros, Xoana and Fulladosa, Xavier and Torras, Joan and Cruzado, Josep M.},
year = {2017},
pmid = {28979773},
pmcid = {PMC5622890},
keywords = {Article, Nefrologia, Nephrotic Syndrome, Steroids, immunosuppresion, minimal change disease, mycophenolate mofetil},
pages = {632--638},
}
Downloads: 0
{"_id":"habYGuLzcG7T85azb","bibbaseid":"sandoval-poveda-draibe-prezoller-daz-ballarn-saurina-marco-etal-efficacyofmycophenolatetreatmentinadultswithsteroiddependentfrequentlyrelapsingidiopathicnephroticsyndrome-2017","downloads":0,"creationDate":"2018-10-11T03:50:31.464Z","title":"Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome","author_short":["Sandoval, D.","Poveda, R.","Draibe, J.","Pérez-Oller, L.","Díaz, M.","Ballarín, J.","Saurina, A.","Marco, H.","Bonet, J.","Barros, X.","Fulladosa, X.","Torras, J.","Cruzado, J. M."],"year":2017,"bibtype":"article","biburl":"https://bibbase.org/zotero/Bibliotecacst","bibdata":{"bibtype":"article","type":"article","title":"Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome","volume":"10","issn":"2048-8505","doi":"10.1093/ckj/sfx035","abstract":"BACKGROUND: This study assessed the efficacy of therapy with mycophenolate (MF) and reduced doses of steroids in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome (SD/FR-INS). METHODS: Twenty-nine nephrotic patients (including 16 males and 13 females; mean age: 40 years, range: 18-74) were treated. Starting doses of MF were 2000 mg/day for mofetil MF (1500 mg/day in one patient) or 1440 mg/day for sodium MF. The initial prednisone (PDN) dose was 10 mg/day in 14 patients, 5 mg/day in two patients and no steroids in one patient. In the remaining 12 patients, moderate initial doses of PDN were administered (mean: 23.7 mg/day, range: 15-40), tapering to 10 mg/day after 1 month. RESULTS: Nephrotic syndrome remission was achieved in 27/29 cases (93.1%) (25 complete, 2 partial). Two patients showed resistance to the prescribed schedule. The first cycle of MF therapy was concluded in 20 patients after a mean (range) of 16.9 months (12-49). Maintenance of remission was observed in 11 of these 20 cases (55%) after a mean follow-up of 32.8 months (12-108). In nine patients with nephrotic syndrome relapse after tapering of MF (MF dependency), the same MF-PDN schedule was restarted, leading again to remission in all nine. The remaining seven MF-sensitive patients are still receiving their first therapeutic cycle. To date, the mean time under therapy in the 27 MF-sensitive patients is 38 months (4-216). Regarding complications, only minor digestive disorders and a slight decrease in blood haemoglobin levels were observed in a few patients. CONCLUSIONS: MF plus reduced doses of PDN is an effective and well-tolerated therapy for adult SD/FR-INS. Though MF dependence is observed, its low toxicity could allow long periods of therapy if it is required to maintain nephrotic syndrome remission.","language":"eng","number":"5","journal":"Clinical Kidney Journal","author":[{"propositions":[],"lastnames":["Sandoval"],"firstnames":["Diego"],"suffixes":[]},{"propositions":[],"lastnames":["Poveda"],"firstnames":["Rafael"],"suffixes":[]},{"propositions":[],"lastnames":["Draibe"],"firstnames":["Juliana"],"suffixes":[]},{"propositions":[],"lastnames":["Pérez-Oller"],"firstnames":["Laureà"],"suffixes":[]},{"propositions":[],"lastnames":["Díaz"],"firstnames":["Montserrat"],"suffixes":[]},{"propositions":[],"lastnames":["Ballarín"],"firstnames":["José"],"suffixes":[]},{"propositions":[],"lastnames":["Saurina"],"firstnames":["Anna"],"suffixes":[]},{"propositions":[],"lastnames":["Marco"],"firstnames":["Helena"],"suffixes":[]},{"propositions":[],"lastnames":["Bonet"],"firstnames":["Josep"],"suffixes":[]},{"propositions":[],"lastnames":["Barros"],"firstnames":["Xoana"],"suffixes":[]},{"propositions":[],"lastnames":["Fulladosa"],"firstnames":["Xavier"],"suffixes":[]},{"propositions":[],"lastnames":["Torras"],"firstnames":["Joan"],"suffixes":[]},{"propositions":[],"lastnames":["Cruzado"],"firstnames":["Josep","M."],"suffixes":[]}],"year":"2017","pmid":"28979773","pmcid":"PMC5622890","keywords":"Article, Nefrologia, Nephrotic Syndrome, Steroids, immunosuppresion, minimal change disease, mycophenolate mofetil","pages":"632–638","bibtex":"@article{sandoval_efficacy_2017,\n\ttitle = {Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome},\n\tvolume = {10},\n\tissn = {2048-8505},\n\tdoi = {10.1093/ckj/sfx035},\n\tabstract = {BACKGROUND: This study assessed the efficacy of therapy with mycophenolate (MF) and reduced doses of steroids in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome (SD/FR-INS).\nMETHODS: Twenty-nine nephrotic patients (including 16 males and 13 females; mean age: 40 years, range: 18-74) were treated. Starting doses of MF were 2000 mg/day for mofetil MF (1500 mg/day in one patient) or 1440 mg/day for sodium MF. The initial prednisone (PDN) dose was 10 mg/day in 14 patients, 5 mg/day in two patients and no steroids in one patient. In the remaining 12 patients, moderate initial doses of PDN were administered (mean: 23.7 mg/day, range: 15-40), tapering to 10 mg/day after 1 month.\nRESULTS: Nephrotic syndrome remission was achieved in 27/29 cases (93.1\\%) (25 complete, 2 partial). Two patients showed resistance to the prescribed schedule. The first cycle of MF therapy was concluded in 20 patients after a mean (range) of 16.9 months (12-49). Maintenance of remission was observed in 11 of these 20 cases (55\\%) after a mean follow-up of 32.8 months (12-108). In nine patients with nephrotic syndrome relapse after tapering of MF (MF dependency), the same MF-PDN schedule was restarted, leading again to remission in all nine. The remaining seven MF-sensitive patients are still receiving their first therapeutic cycle. To date, the mean time under therapy in the 27 MF-sensitive patients is 38 months (4-216). Regarding complications, only minor digestive disorders and a slight decrease in blood haemoglobin levels were observed in a few patients.\nCONCLUSIONS: MF plus reduced doses of PDN is an effective and well-tolerated therapy for adult SD/FR-INS. Though MF dependence is observed, its low toxicity could allow long periods of therapy if it is required to maintain nephrotic syndrome remission.},\n\tlanguage = {eng},\n\tnumber = {5},\n\tjournal = {Clinical Kidney Journal},\n\tauthor = {Sandoval, Diego and Poveda, Rafael and Draibe, Juliana and Pérez-Oller, Laureà and Díaz, Montserrat and Ballarín, José and Saurina, Anna and Marco, Helena and Bonet, Josep and Barros, Xoana and Fulladosa, Xavier and Torras, Joan and Cruzado, Josep M.},\n\tyear = {2017},\n\tpmid = {28979773},\n\tpmcid = {PMC5622890},\n\tkeywords = {Article, Nefrologia, Nephrotic Syndrome, Steroids, immunosuppresion, minimal change disease, mycophenolate mofetil},\n\tpages = {632--638},\n}\n\n","author_short":["Sandoval, D.","Poveda, R.","Draibe, J.","Pérez-Oller, L.","Díaz, M.","Ballarín, J.","Saurina, A.","Marco, H.","Bonet, J.","Barros, X.","Fulladosa, X.","Torras, J.","Cruzado, J. M."],"key":"sandoval_efficacy_2017","id":"sandoval_efficacy_2017","bibbaseid":"sandoval-poveda-draibe-prezoller-daz-ballarn-saurina-marco-etal-efficacyofmycophenolatetreatmentinadultswithsteroiddependentfrequentlyrelapsingidiopathicnephroticsyndrome-2017","role":"author","urls":{},"keyword":["Article","Nefrologia","Nephrotic Syndrome","Steroids","immunosuppresion","minimal change disease","mycophenolate mofetil"],"downloads":0,"html":"","metadata":{"authorlinks":{}}},"search_terms":["efficacy","mycophenolate","treatment","adults","steroid","dependent","frequently","relapsing","idiopathic","nephrotic","syndrome","sandoval","poveda","draibe","pérez-oller","díaz","ballarín","saurina","marco","bonet","barros","fulladosa","torras","cruzado"],"keywords":["article","nefrologia","nephrotic syndrome","steroids","immunosuppresion","minimal change disease","mycophenolate mofetil"],"authorIDs":[],"dataSources":["TR9pX4mH5rDPr29Zo"]}